T-cell antigen discovery (T-CAD) assay: A novel technique for identifying T cell epitopes

Journal of Immunological Methods

Volumn 256, Issue 1-2, 2001, Pages 107-119

  Turner, Michael J ^a   Abdul Alim, C Siddiq ^a   Willis, Richard A ^a   Fisher, Terrence L ^a   Lord, Edith M ^a   Frelinger, John G ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Major histocompatability complex; Prostate specific antigen; T cell epitopes

Indexed keywords

BACTERIUM LYSATE; CHELATE; EPITOPE; HISTIDINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NICKEL; OVALBUMIN; PEPTIDE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ANTIGEN; T LYMPHOCYTE ANTIGEN;

ANALYTIC METHOD; ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; COLORIMETRY; CONTROLLED STUDY; EVALUATION; HYBRIDOMA; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MONITORING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SECRETORY CELL; T LYMPHOCYTE; TECHNIQUE; VALIDATION PROCESS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; CELL LINE; CELLS, CULTURED; EPITOPES, T-LYMPHOCYTE; ESCHERICHIA COLI; HISTIDINE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HYBRIDOMAS; LYMPHOCYTE ACTIVATION; MICE; MICROSPHERES; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; RECOMBINANT FUSION PROTEINS; SEQUENCE DELETION; T-LYMPHOCYTES; TRANSFECTION;

BACTERIA (MICROORGANISMS);

EID: 0035480182     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(01)00436-7     Document Type: Article

References (54)

1. Phenotypic analysis of antigen-specific T lymphocytes
2. Differential epitope expression of Ly-48 (mouse leukosialin)
3. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
4. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
5. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
6. The cell biology of antigen processing and presentation
7. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
8. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes
9. Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: Sequence motif, quantitative binding, and molecular modeling of the complex
10. H-2Dd exploits a four residue peptide binding motif
11. Immunogenic (tum-) variants of mouse tumor P815: Cloning of the gene of tum-antigen P91A and identification of the tum-mutation
12. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
13. Structures of an MHC class II molecule with covalently bound single peptides
14. Complex regulation of class II gene expression: Analysis with class II mutant cell lines
15. H-2 antigen requirements in the in vitro induction of SV40-specific cytotoxic T lymphocytes
16. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers
17. Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells
18. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
19. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry
20. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
21. Identification of self peptides bound to purified HLA-B27
22. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
23. Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene
24. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages
25. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients
26. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells
27. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor
28. Pathways for the processing and presentation of antigens to T cells
29. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells
30. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
31. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
32. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens
33. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
34. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
35. Induction of antitumor immunity using bone marrow-generated dendritic cells
36. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells
37. Chemistry of peptides associated with MHC class I and class II molecules
38. MHC ligands and peptide motifs: First listing
39. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation
40. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis
41. Efficient in vivo induction of CTL by cell-associated covalent H-2Kd-peptide complexes
42. Sequence analysis of peptides bound to MHC class II molecules
43. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
44. LacZ inducible, antigen/MHC-specific T cell hybrids
45. LacZ inducible, antigen/MHC-specific T cell hybrids
46. Structural requirements for the interaction between peptide antigens and I-Ed molecules
47. Antigen analogs/MHC complexes as specific T cell receptor antagonists
48. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells
49. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules
50. Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells
51. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue
52. A disease-related epitope of Torpedo acetylcholine receptor. Residues involved in I-Ab binding, self-nonself discrimination, and TCR antagonism
53. Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes
54. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses